However, some people are not that lucky. They may suffer from bones defect such as osteoporosis, arthritis, or knee pain because of several reasons. To get your life back into normal, you need to go to best Orthopaedic & Spine Cente. There will be many experts in bone who are ready to give you therapy.

In Osc-ortho.com, you can also apply for bone surgery. Orthopaedic & Spine Cente receives order from any states in America as well. Equipped by sophisticated technology, such as new MRI equipments, you will be safe here. All the examination will be informed to the patients honestly.

While previous studies have linked smoking to increased breast cancer risk, they have not been accompanied by molecular biology studies to determine why. In this present study, scientists reveal a link between nicotine itself and breast cancer risk – not just the other non-nicotine components of smoking.

You can read about this study in The Journal of the National Cancer Institute, August 23^rd (2010) issue.

Yuan-Soon Ho, Ph.D., Taipei Medical University, and team examined 276 breast tumor samples from anonymous donors to Taipei Medical University Hospital. They wanted to determine whether subunits of the nicotinic acetylcholine receptor were overexpressed in breast cancer cells compared with other normal cells.

They found that the alpha 9 subunit nAChR (α9-nAchR) was overexpressed in human breast cancer cells. Expression was significantly higher in advanced stage breast cancer than in its early stages.

The investigators reveal that when α9-nAchRs were reduced, tumor growth in the laboratory was inhibited. The opposite promoted cancer growth – if α9-nAchRs was increased, or when treating more normal breast cells with nicotine, the development of cancer characteristics grew.

The researchers wrote:

These results imply that receptor-mediated carcinogenic signals play a decisive role in biological functions related to human breast cancer development.

The authors stress that theirs was a small study with only Asian patients involved. Breast cancer incidence in Taiwan is low.

Ilona Linnoila, M.D., of the Center for Cancer Research at the National Cancer Institute, in an accompanying editorial, writes that the study:

..suggests not only that smoking could be causally related to breast carcinogenesis but also that nicotine could directly contribute to the molecular mechanism of carcinogenesis in addition to indirectly contributing by promoting addiction to smoking.

Better understanding of the molecular mechanisms of the cholinergic pathways will lead to more opportunities for intervention and prevention of tobacco toxicity

“Overexpression and Activation of the {alpha}9-Nicotinic Receptor During Tumorigenesis in Human Breast Epithelial Cells”
Chia-Hwa Lee, Ching-Shui Huang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Yu-Jia Chang, Ka-Wai Tam, Po-Li Wei, Tzu-Chun Cheng, Jan-Show Chu, Li-Ching Chen, Chih-Hsiung Wu, Yuan-Soon Ho
JNCI (Journal of the National Cancer Institute), doi:10.1093/jnci/djq300

Written by Christian Nordqvist
Copyright: Medical News Today

Hitchens is well known to be a heavy cigarette smoker. Although he appeared to have quit in 2008, various sources report that he fell off the nicotine-wagon. Fox News writes that in 2003 he admitted that his alcohol intake was enough to kill or stun the average mule.
Hitchen said:

I have been advised by my physician that I must undergo a course of chemotherapy on my esophagus. This advice seems persuasive to me. I regret having had to cancel so many engagements at such short notice.

Hitchens, an atheist, has been identified as being an exponent of the new atheism movement. He describes himself as a believer in the philosophical values of the Age of Enlightenment. He claims that the concept of God as a supreme being is a totalitarian belief that undermines individual freedom, and that scientific discovery, and free expression should replace religion, which is an obstacle for these things, as a means of teaching ethics and defining human civilization. In his 2007 book God is Not Great, he wrote at length on atheism and the nature of religion. He is an admirer of George Orwell, Thomas Paine, and Thomas Jefferson.

He has both US and British citizenships.

What is cancer of the esophagus (Esophageal cancer)?

Esophageal cancer occurs in the esophagus which is a long hollow tube that runs from the throat to the stomach. The esophagus carries the food that is swallowed all the way to the stomach to be digested.

Esophageal cancer usually begins in the cells that line the inside of the esophagus. Cancer happens when some of the cells multiply in an abnormal way, causing a growth called a tumor to form. Tumors can be benign (not cancerous) or malignant (cancerous). They can occur in any part of the body where the cells multiply abnormally.

Esophageal cancer is not common. In areas of the world, such as Asia and parts of Africa, esophageal cancer is much more common.

Men and people over the age of 55 are most commonly affected esophageal cancer.

Types of cancer of the esophagus:

• Squamous cell carcinoma forms in the upper part of the esophagus when cells on the inside lining of the esophagus multiply abnormally.
• Adenocarcinoma of the esophagus forms in the lower part of the esophagus when cells inside the mucous glands that line the esophagus multiply abnormally. Mucous glands produce a slimy substance to help food slide down the esophagus more easily.
• Other rare types. Rare forms of esophageal cancer include choriocarcinoma, lymphoma, melanoma, sarcoma and small cell cancer.

For more information on cancer of the esophagus, click here.

Written by Christian Nordqvist
Copyright: Medical News Today

The study confirms previous research in which study author Stephen G. Grant, Ph.D., associate professor of environmental and occupational health at Pitt’s Graduate School of Public Health, discovered evidence of abnormalities in the HPRT gene located on the X chromosome in cord blood from newborns of non-smokers exposed to environmental tobacco smoke.

In the current study, Dr. Grant confirmed smoke-induced mutation in another gene called glycophorin A, or GPA, that is representative of oncogenes – genes that transform normal cells into cancer cells and cause solid tumors. The GPA mutation was the same level and type in newborns of mothers who were active smokers and of non-smoking mothers exposed to tobacco smoke. Likewise, the mutations were discernable in newborns of women who had stopped smoking during their pregnancies, but who did not actively avoid secondhand smoke.

“These findings back up our previous conclusion that passive, or secondary, smoke causes permanent genetic damage in newborns that is very similar to the damage caused by active smoking,” said Dr. Grant. “By using a different assay, we were able to pick up a completely distinct yet equally important type of genetic mutation that is likely to persist throughout a child’s lifetime. Pregnant women should not only stop smoking, but be aware of their exposure to tobacco smoke from other family members, work and social situations.”

The research was funded by grants from the National Institute of Child Health and Human Development and the University of Pittsburgh Competitive Medical Research Fund.

Source:
Clare Collins
University of Pittsburgh Schools of the Health Sciences

You can read the consensus report by experts representing the American Diabetes Association and the American Cancer Society, in the 16 June online before print issue of CA: A Cancer Journal for Clinicians; the print version will appear in the July/August paper edition.

Some evidence suggests that people with diabetes are at a higher risk of developing many types of cancer, and type 2 diabetes and cancer share some risk factors as well as treatments; however, the underlying biology of this overlap is somewhat elusive.

This gap in understanding spurred the American Diabetes Association and the American Cancer Society to bring together experts to address some key questions, for instance, what risk factors are common to both cancer and diabetes, is there a meaningful link between their incidence and prognosis, what might the underlying biological mechanisms be, and do treatments for diabetes affect cancer risk and prognosis?

The experts were asked to investigate each question, identify current gaps in evidence and suggest future strategies so researchers and epidemiologists can work toward closing the gaps.

Here are some points they reached consensus on, and some recommendations they made:

• People with diabetes (mostly type 2), are likely to be at increased risk of developing cancer of the liver, pancreas, endometrium (lining of the uterus), colon, rectum, breast and bladder.
• The evidence, some of which is inconclusive, does not point to a link between diabetes and increased risk of cancer in other parts of the body, and for prostate cancer, having diabetes appears to lower the risk.
• Shared risk factors such as age, obesity, diet and lack of physical activity may explain the link between diabetes and some cancers.
• Biological mechanisms that directly link diabetes and cancer include hyperinsulinemia (too much insulin in the blood), hyperglycemia (too much sugar in the blood), and inflammation.
• Being physically active, managing weight, and keeping to a healthy diet, things that we should all do for sake of our health anyway, reduce the risk and improve outcomes of type 2 diabetes and some cancers.
• Doctors and healthcare professionals should encourage all patients with diabetes to have the recommended cancer screening for their age and sex.
• On the whole, cancer risk should not be a major factor affecting choice of diabetes therapy for most patients. However, some specific cases, such as patients at higher risk of cancer, or at higher risk of recurrence of certain cancers, may need more careful consideration.
• There is limited evidence that specific drugs influence cancer risk. Suggestions that they do could be a result of certain side effects such as impact on body weight and hyperinsulinemia, as well as the complex and progressive way that hyperglycemia and drugs interact in type 2 diabetes.
• The evidence on metformin (an oral anti-diabetic drug) is still patchy, but what there is suggests it is linked to a lower risk of cancer.
• Similarly, early evidence would suggest that exogenous insulin (that is introduced into the body) is linked to a higher risk of cancer.
• More research is needed to confirm or clarify this early evidence, and to evaluate the possible links between insulin and other diabetes medications and cancer risk.

In many respects the report points to a multitude of uncertain issues, and possibly furnishes more questions than answers, for reasons that Dr Edward Giovannucci, co-chair of the consensus report group, attempted to explain:

“Traditionally there hasn’t been much overlap between research in cancer and in diabetes.”

“But recently it’s become clearer that there are fascinating links between the two. Our summary may raise more questions than provide answers, but we hope that it will spur additional studies,” he added.

His colleague and co-chair Dr David M. Harlan said that for the vast majority of diabetes patients, worrying about which diabetes treatment is better or worse as far as cancer is concerned will not be an issue.

“Only patients with a very high risk for cancer occurrence, or re-occurrence, may wish to carefully consider their options. Even then, the association appears to exist for some cancer types, and not for others,” said Harlan, concluding that “we have much to learn”.

“Diabetes and Cancer: A Consensus Report.”
Edward Giovannucci, David M. Harlan, Michael C. Archer, Richard M. Bergenstal, Susan M. Gapstur, Laurel A. Habel, Michael Pollak, Judith G. Regensteiner, and Douglas Yee.
CA Cancer J Clin, published online before print 16 June 2010.
DOI:10.3322/caac.20078

Source: American Cancer Society.

Written by: Catharine Paddock, PhD
Copyright: Medical News Today

Part of the body’s defence system is controlled by a gene called Tumour Necrosis Factor (TNF) that can stop cancers from developing by killing them. But this same response has also been shown to help promote the growth of cancers.

For the first time, scientists at the Cancer Research UK Beatson Institute in Glasgow have shown how TNF turns to the ‘dark side’, helping some cancers to grow and move to new parts of the body. They found that the TNF response is hijacked by two genes linked to cancer.

The two genes are a tumour suppressor gene, that promotes tumour growth when deleted, and a tumour promoter gene that can turn cells cancerous when activated.

In their study, using fruit flies (Drosophila melanogaster), they found that cells which lack a tumour suppressor gene and turn cancerous are targeted and killed by the TNF controlled response. But, if the tumour promoter is also activated, cancer cells are not only able to escape the TNF’s death signal but also produce a signal to help them spread and grow.

The researchers also showed that all three genes need to be involved for the cancer to fully escape control by the body’s defences. If the response is not co-ordinated by TNF, a tumour will develop, but it is a so called benign tumour – unable to spread to other parts of the body.

Dr Marcos Vidal, lead author from Cancer Research UK’s Beatson Institute, said: “This is the first time that the mechanism behind this hijacking of the TNF controlled response to tumours has been demonstrated. The next step is to test if these same interactions are taking place in humans. If it is, we could determine which patients will benefit from drugs that stimulate an inflammatory response and those who would benefit from drugs that dull these signals down, preventing the cancer from using the TNF to spread and grow.”

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “Cancers are a complex interplay and competition between the body’s defences and the cancer’s attempts to grow and spread. This research reveals more about these interactions and could one day open up new approaches for treating cancer.”

Reference

1. Cordero et al, TNF is a tumour promoter in Drosophila (2010) Developmental Cell

Source
Cancer Research UK

The study** shows if England matched Norway and Sweden’s survival rates for breast cancer, 957 deaths could be prevented annually in women whose cancer is diagnosed so late that they usually die within two years of diagnosis.

When breast cancer is caught early, treatment is often milder and more effective. Survival rates soon after diagnosis can be used as an indicator of whether the disease is being caught early or late.

Professor Henrik Møller, lead author from King’s College London, said: “This study has important implications for women in this country. We could prevent nearly a thousand deaths from breast cancer each year by getting the disease diagnosed earlier, particularly in older women.

“These figures show how important it is for women, and GPs, to know the symptoms of breast cancer and to act on them without delay. Going for screening when invited will also help to catch the disease at the earliest stage. Although women over 70 aren’t routinely invited for screening, they can ask their GP for a mammogram.

Each year in England, there are 1,183 excess deaths from breast cancer in England within five years of diagnosis. Of these avoidable deaths, 260 occur within a month of diagnosis, 557 between a month and a year after diagnosis and 140 deaths happen after a year but before two years since diagnosis.

Crucially, 81 per cent of these deaths occur within two years of diagnosis and mainly in older women over 80. This amounts to 957 deaths that should not have happened.

In England, over 38,000 cases of breast cancer are diagnosed each year and, overall, eight out of ten women survive the disease beyond five years. Breast cancer survival has been improving and death rates have fallen in recent decades.

Chris Carrigan, head of the NCIN, said: “We know that many cancers are being diagnosed too late in this country, and this study reveals the scale of the challenge for breast cancer in particular.

“More women are surviving breast cancer than ever before and we know that significant improvements in breast cancer treatment are being made. But we still have work to do to emphasise the benefits of early detection.”

Professor Sir Mike Richards, national cancer director said: “This is an important new study. It highlights the importance of early diagnosis in achieving the best possible survival rates for women with breast cancer.a

“Survival rates have improved in this country over the past decade, but there is more to be done. Over the coming months we shall be looking at what needs to be done to achieve earlier diagnosis.”

Reference

“Breast cancer survival in England, Norway and Sweden: a population-based comparison.”
Møller et al.
International Journal of Cancer. February 2008

Notes

* The researchers compared England’s survival rates with those of Norway and Sweden. This is because these countries collect data on every cancer patient in the country. In other European countries, national data are often not routinely collected.

**The study looked at all survival rates from all cases of breast cancer diagnosed between 1996 and 2004.

Source
Cancer Research UK

A case report published in the World Journal of Gastroenterology addresses this problem. The diagnostic pathology team led by Associate Professor Dr. Hayashi at the Department of Pathology, Nagasaki University Hospital in Japan collaborated with Professor Nagayasu, Department of the 1st Surgery and Professor Uetani, Department of Radiology, to investigate how the specific “clear cell” change occurs, a patient’s underlying disease and choice of chemotherapy, and the prognosis for future patients of this rare cancer.

The patient was a 56-year-old Japanese man with a 3-year history of hepatitis B virus (HBV) infection. The follow-up echo revealed a tumor of the liver. CT and MRI suggested hepatocellular carcinoma (HCC); a cancer of liver cells. The patient had surgery and the tumor was diagnosed as the rare “clear cell ICC”, not a conventional HCC.

Unlike reported cases, this patient had HBV infection as the underlying disease. The cell of conventional ICC is usually small and its nucleus occupies a large part of the cell. Clear cell ICC consists of larger cells with copious cytoplasm possibly caused by mucin, lipid, glycogen or by another unknown reason. Therefore the cells look clear. The cancer cells originating from bile ducts often produce much mucin, however the clear cells in this case did not contain mucin, and had a little glycogen.

The literature review disclosed that the risk of metastasis or recurrence is low after the removal of the cancer. There is not enough evidence for the use of any particular treatment including chemotherapy. Therefore, careful follow-up and the acquisition of more case records are important to obtain more evidence on this cancer.

Reference:
Toriyama E, Nanashima A, Hayashi H, Abe K, Kinoshita N, Yuge S, Nagayasu T, Uetani M, Hayashi T. A case of intrahepatic clear cell cholangiocarcinoma. World J Gastroenterol 2010; 16(20): 2571-2576

Source:
Lin Tian
World Journal of Gastroenterology

The compounds – fluorescent inhibitors of the enzyme cyclooxygenase-2 (COX-2) – could have broad applications for detecting tumors earlier, monitoring a tumor’s transition from pre-malignancy to more aggressive growth, and defining tumor margins during surgical removal.

“We’re very excited about these new agents and are moving forward to develop them for human clinical trials,” said Lawrence Marnett, Ph.D., the leader of the Vanderbilt University team that developed the compounds, which are described in the May 1 issue of Cancer Research.

COX-2 is an attractive target for molecular imaging. It’s not found in most normal tissues, and then it is “turned on” in inflammatory lesions and tumors, Marnett explained.

“COX-2 is expressed at the earliest stages of pre-malignancy – in pre-malignant lesions, but not in surrounding normal tissue – and as a tumor grows and becomes increasingly malignant, COX-2 levels go up,” Marnett said.

Compounds that bind selectively to COX-2 – and carry a fluorescent marker – should act as “beacons” for tumor cells and for inflammation.

Marnett and his colleagues previously demonstrated that fluorescent COX-2 inhibitors – which they have now dubbed “fluorocoxibs” – were useful probes for protein binding, but their early molecules were not appropriate for cellular or in vivo imaging.

“It was a real challenge to make a compound that is COX-2 selective (doesn’t bind to the related COX-1 enzyme), has desirable fluorescence properties, and gets to the tissue in vivo,” Marnett said.

To develop such compounds, Jashim Uddin, Ph.D., research assistant professor of Biochemistry, started with the “core” chemical structure of the anti-inflammatory medicines indomethacin and celecoxib. He then tethered various fluorescent parts to the core structure, ultimately synthesizing more than 200 compounds. The group tested each compound for its interaction with purified COX-2 and COX-1 proteins and then assessed promising compounds for COX-2 selectivity and fluorescence in cultured cells and in animals. Two compounds made the cut.

In studies led by senior research specialist Brenda Crews, the investigators evaluated the potential of these compounds for in vivo imaging using three different animal models: irritant-induced inflammation in the mouse foot pad; human tumors grafted into mice; and spontaneous tumors in mice.

In each case, the two fluorocoxibs – injected intravenously or into the abdominal cavity – accumulated in the inflamed or tumor tissue, giving it a fluorescent “glow.”

To move the agents toward human clinical trials, the team will conduct additional toxicology and pharmacology testing and develop the tools for particular settings that are amenable to fluorescence imaging, such as skin or sites accessible by endoscope (e.g., esophagus and colon).

In the esophagus, for example, a pre-malignant lesion called Barrett’s esophagus can transition to a low-grade dysplasia, then to a high-grade dysplasia, and finally to malignant cancer, which has a one-year survival of only 10 percent. For a patient with Barrett’s esophagus, detecting the transition to dysplasia is critical. The problem is that dysplasia is not visibly different from the pre-malignant Barrett’s lesion, so physicians collect random biopsy samples – which might miss areas of dysplasia.

“If instead, the physician could look through the endoscope and see a nest of cells lighting up with these fluorocoxibs – that is where they could biopsy,” Marnett said.

“Because COX-2 levels increase during cancer progression in virtually all solid tumors, we think these imaging tools will have many, many different applications.”

The investigators also are exploring using the compounds to target delivery of chemotherapeutic drugs directly to COX-2-expressing cells – by tethering an anti-cancer drug instead of a fluorescent marker to the COX-2 inhibitor core.

The National Institutes of Health, the Medical Free-Electron Laser Program of the U.S. Department of Defense, XL TechGroup and the New York Crohn’s Foundation supported the research. The Vanderbilt Cell Imaging Shared Resource and the Vanderbilt University Institute of Imaging Science enabled the cellular and animal imaging.

Marnett is director of the A. B. Hancock, Jr. Memorial Laboratory for Cancer Research, director of the Vanderbilt Institute of Chemical Biology, Mary Geddes Stahlman Professor of Cancer Research, and professor of Biochemistry, Chemistry, and Pharmacology.

Source:
Craig Boerner
Vanderbilt University Medical Center

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

Source
U.S. Food and Drug Administration